TABLE 4.
Treatment regimen outcomes by grade of malignancy
| Low grade | High grade | |
|---|---|---|
| Total (%) | 54 a | 70 |
| Responders (%) | 45 (83.3) | 46 (65.7) |
| Complete remission | 2 (3.7) | 15 (21.4) |
| Partial remission | 16 (29.6) | 13 (18.6) |
| Stable disease | 27 (50.0) | 15 (21.4) |
| Mixed response | 0 (0.0) | 3 (4.3) |
| Non‐responders (%) | 9 (16.7) | 24 (34.3) |
| Disease progression | 3 (5.6) | 13 (18.6) |
| No response | 6 (11.1) | 11 (15.7) |
| Response status (%) | ||
| Ongoing | 25 (46.3) | 10 (14.3) |
| Ceased | 19 (35.2) | 36 (51.4) |
| Lost to follow‐up | 1 (1.9) | 0 (0.0) |
| Response duration (months) | ||
| Median | 20.35 | 6.5 |
| Range | 1.7‐91.7 | 0–93.2 |
a
Low‐grade malignancy encompassed acoustic neuroma, atypical spitz naevus, desmoid tumor, Langerhans cell Histiocytosis, Non‐Langerhans histiocytosis, hemangioma, hemangioendothelioma, kaposiform lymphangiomatosis, low‐grade glioma, and plexiform neurofibroma.